Yael C. Cohen

Ha Lokhamim St 62, 5822012
Holon, TA 58220, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 03, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

Can Belantamab mafodotin cause macro LDH?

Can Belantamab mafodotin cause macro LDH?

Journal: Leukemia & lymphoma

Published: April 16, 2026

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS.

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS.

Journal: Leukemia

Published: February 19, 2026

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

Journal: Blood advances

Published: January 30, 2026

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

Journal: Blood advances

Published: January 30, 2026

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Journal: Annals of hematology

Published: January 21, 2026

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Journal: Cancers

Published: January 13, 2026

Double Dummy Design for Blinding Studies With Automated Insulin Delivery Systems: A Proof of Concept Trial.

Double Dummy Design for Blinding Studies With Automated Insulin Delivery Systems: A Proof of Concept Trial.

Journal: Journal of diabetes science and technology

Published: January 07, 2026

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Journal: The New England journal of medicine

Published: December 08, 2025

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.

Journal: Future oncology (London, England)

Published: October 08, 2025

Current experiences with teclistamab in patients with multiple myeloma and renal impairment.

Current experiences with teclistamab in patients with multiple myeloma and renal impairment.

Journal: Expert review of hematology

Published: September 29, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026